Results 141 to 150 of about 7,704 (220)

Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings. [PDF]

J Nephrol
Peruzzi L, Leporati M, Pediatric Oxal Turin Working Group.   +2 more
europepmc   +1 more source

Effect of the allelic background on the phenotype of primary hyperoxaluria type I. [PDF]

Curr Opin Nephrol Hypertens
Mandrile G, Cellini B, Ferraro PM.
europepmc   +1 more source

Assessment of hypervolemia by cyclic 3 ` 5 `-guanosine monophosphate in pediatric patients on hemodialysis [PDF]

, 1999
Gerzer, Rupert, Holzgartner, Verena, Klare, Bernd, Schiffl, Helmut, Sitter, Thomas, Toepfer, Marcel, Wolfram, Gernot   +6 more
core   +1 more source

A Minor Haplotype Variant Determines the Pathogenicity of the p.Ile279Thr Substitution in the Primary Hyperoxaluria Type 1 Gene, AGXT. [PDF]

J Inherit Metab Dis
Ruta L, Cogal AG, Pampalone G, Sas DJ, Lieske JC, Rumsby G, Cellini B, Harris PC.   +7 more
europepmc   +1 more source

Stage I Seminoma of the Testis [PDF]

, 1991
Allhoff, E. P., Liedke, S. G., Riese, W. de, Schneider, B., Stief, Christian Georg   +4 more
core   +1 more source

Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1. [PDF]

Pediatr Nephrol
Saffe S, Doerry K, Büscher AK, Hansen M, Rohmann M, Kanzelmeyer N, Latta K, Kemper MJ, Loos S.   +8 more
europepmc   +1 more source

PHYOX3: Nedosiran Long-Term Safety and Efficacy in Patients With Primary Hyperoxaluria Type 1. [PDF]

Kidney Int Rep
Lieske JC, Ariceta G, Groothoff JW, Lipkin G, Moochhala SH, Schalk G, Sellier-Leclerc AL, Torres SE, Rawson V, Zhou J, Hoppe B.   +10 more
europepmc   +1 more source

Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria. [PDF]

Kidney Int Rep
Hoppe B, Martin-Higueras C, Borghese L, Kaspar S, Reusch B, Beck BB, Walli A, Janzen E, Hegert S, Janzen N, Hohenfellner K.   +10 more
europepmc   +1 more source

Primary hyperoxaluria type 1 diagnosis in adult dialysis patients: prediction model assessment in a group of Italian patients. [PDF]

J Nephrol
Ferraro PM, Arbustini E, Bellino D, Caletti C, Capelli I, Capolongo G, Caruso MR, Cianfrone P, D'Alessandro MM, Di Luca M, Gambaro G, Palmisano A, Ranghino A, Santagostino Barbone G, Viazzi F, Zambianchi L, Mandrile G.   +16 more
europepmc   +1 more source

Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1. [PDF]

Clin Pharmacokinet
Zhang S, Gamallo P, Rawson V.
europepmc   +1 more source